Issue link: https://uberflip.scri.com/i/1529641
1125/24SCR018-7/R3 Abstract & Presentation Calendar ASH® 2024 4 Saturday Sunday Monday SUNDAY, DECEMBER 8 TH 9:30am - 1:30pm Pacific Time (continued) Time Presentation Time Session Location Presentation Type Abstract Number Presentation Title 1st Author *SCRI First Author in Bold SCRI-Affiliated Coauthors Session Name 9:30 - 11:00am 9:45am San Diego Convention Center, Room 30 Oral 512 Durable Clinical Benefits with Exagamglogene Autotemcel for Transfusion-Dependent Thalassemia Locatelli F Frangoul H Gene Therapies: Gene Editing and Replacement Therapies for Hemoglobinopathies: From Bench to Bedside 9:30 - 11:00am 10:00am Marriott Marquis, Pacific Ballroom Salons 18-19 Oral 495 Teclistamab, Daratumumab, and Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Results from the Majestec-2 Cohort a and Trimmâ€'2 Studies D'Souza A Matous JV Multiple Myeloma: Pharmacologic Therapies: Targeting BCMA 9:30 - 11:00am 10:00am San Diego Convention Center, Room 30 Oral 513 Initial Results from the BEACON Clinical Study: A Phase 1/2 Study Evaluating the Safety and Efficacy of a Single Dose of Autologous CD34+ Base Edited Hematopoietic Stem Cells (BEAM-101) in Patients with Sickle Cell Disease with Severe Vaso-Occlusive Crises Gupta AO Frangoul H Gene Therapies: Gene Editing and Replacement Therapies for Hemoglobinopathies: From Bench to Bedside 9:30 - 11:00am 10:15am San Diego Convention Center, Ballroom 20AB Oral 460 Updated Analysis of Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Nonbulky, Early- Stage Classical Hodgkin Lymphoma Abramson JS Burke J, Gandhi M, Yasenchak C Hodgkin Lymphomas: Clinical and Epidemiological: Potentially Practice- Changing Trials in Hodgkin Lymphoma 9:30 - 11:00am 10:15am Marriott Marquis, Pacific Ballroom Salons 24-26 Oral 526 Real-World Early Outcomes of Second-Line Axicabtagene Ciloleucel (Axi-Cel) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) Lee DC Tees MT Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: CAR-T Cell Therapy in Action: Real-World Outcomes in Lymphoma 9:30 - 11:00am 10:30am Manchester Grand Hyatt, Harbor Ballroom DEFG Oral 479 Efficacy and Safety of Asciminib in Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Interim Results from the Phase 2 ASC2ESCALATE Trial in the Cohort of Patients (Pts) after 1 Prior Tyrosine Kinase Inhibitor (TKI) Atallah EL Levy MY, Andorsky D, Bremer CT Chronic Myeloid Leukemia: Novel Molecules in Clinical Practice 9:30 - 11:00am 10:30am San Diego Convention Center, Ballroom 20CD Oral 467 Initial Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDACTM Degrader, in Patients with Non-Hodgkins Lymphoma Horwitz S Tees MT T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: When Old Meets New in T Cell Lymphomas 12:00 - 1:30pm 1:15pm Marriott Marquis, San Diego Ballroom AB Oral 594 Pharmacodynamic Signatures and Correlatives of Response in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Talquetamab or Teclistamab Plus Daratumumab and Pomalidomide Vishwamitra D Matous JV Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Resistance and Response to Anti- Myeloma Therapies